Contract Research & Services
Today in Contract Research & Services

Contract Research & Services

Synairgen reports positive safety data for SNG001 in phase 2 COPD trial Synairgen said that its antiviral therapy SNG001 has so far registered positive safety data in an ongoing phase 2 trial in patients with chronic obstructive pulmonary disease (COPD). Contract Research & Services > Clinical Trials > News

Latest Contract Research & Services News by Sector

Select a sector from the list or browse by sector below:

Clinical Trials

Ironwood Pharmaceuticals starts Phase IIIb study of linaclotide in adult patients with IBS-C
Ironwood Pharmaceuticals has started a phase IIIb clinical trial evaluating the efficacy and safety of linaclotide 290 mcg on multiple abdominal symptoms in addition to pain, including bloating and discomfort, in adult patients with irritable bowel syndrome with constipation (IBS-C).
Contract Research & Services > Clinical Trials > News
Pfizer begins pivotal phase 3 program for investigational hemophilia B gene therapy
Pfizer and Spark Therapeutics announced that Pfizer initiated a Phase 3 open-label, multi-center, lead-in study (NCT03587116) to evaluate the efficacy and safety of current factor IX prophylaxis replacement therapy in the usual care setting.
Contract Research & Services > Clinical Trials > News

Contract Research

RXi Pharmaceuticals enters into research collaboration with Iovance Biotherapeutics
RXi Pharmaceuticals has partnered with Iovance Biotherapeutics to evaluate its sd-rxRNA therapeutic compounds with the latter’s autologous cell therapy based on tumor-infiltrating lymphocytes (TILs) for the use in the treatment of cancer.
Contract Research & Services > Contract Research > News
NetVation DL Medicine enters into research collaboration with Pfizer
Chinese biotechnology company NetVation DL Medicine, which is focused on the discovery and development of novel drug candidates, has entered into a two-year research collaboration with Pfizer.
Contract Research & Services > Contract Research > News

Contract Services

Mylan to buy global marketing rights of Mapi’s Glatiramer acetate product
Mylan has agreed to acquire global marketing rights of Israel-based Mapi Pharma’s GA Depot, a long-acting once-monthly Glatiramer acetate product.
Contract Research & Services > Contract Services > News
Ionis licenses to Akcea global rights to inotersen in $1.7bn deal
By PBR Staff Writer
Ionis Pharmaceuticals has licensed to Akcea Therapeutics worldwide rights to inotersen and AKCEA-TTR-LRx, formerly IONIS-TTR-LRx, in a transaction potentially worth about $1.7bn.
Contract Research & Services > Contract Services > News